Anzeige
Mehr »
Sonntag, 08.06.2025 - Börsentäglich über 12.000 News
5-Dollar-Kupfer. KI-Infrastruktur. Energiewende. Vizsla Copper hat die Pfunde im Boden, die jetzt zählen.
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

Aktuelle News von FierceBiotech

  • 24 h
  • letzte 200 News
ZeitAktuelle Nachrichten
16.05.BioMarin inks $270M Inozyme buyout, bagging phase 3 prospect in first M&A move of the Sabry era
16.05.Eli Lilly strengthens RNA pipeline with $1.3B biobucks hearing loss pact
16.05.HCW Biologics clings on with $5M lifeline to fund phase 1 alopecia trial
15.05.Pathos AI secures $365M series D to fund trial of Novo Nordisk solid tumor drug
15.05.Kinase inhibitor biotech Enliven calls time on phase 1 HER2 solid tumor program
15.05.FDA delays decision on Biohaven's rare disease drug filing, plans adcomm
14.05.RA Capital's biotech incubator lays off staffers: Stat
14.05.ADC Therapeutics drops only clinical-stage drug after reviewing phase 1 leukemia data
14.05.Allogene lays off 28% of staff to extend runway amid delays to CAR-T updates
14.05.Alumis' Acelyrin merger back on track after shareholders unswayed by activist investor
14.05.Novo Nordisk inks $2.2B deal for Septerna's preclinical obesity programs
14.05.Kyverna lays off 16% of staff as autoimmune CAR-T plans pick up pace
14.05.GSK pays $1.2B upfront for Boston Pharmaceuticals' lead liver disease drug
13.05.Arcturus stops work on early-stage vaccine programs in effort to 'streamline resources'
13.05.Erasca enters another era, seeks partner for ph. 3 ex-Novartis asset
13.05.Atara lays off more staff this year despite FDA lifting clinical hold
13.05.GSK axes $625M TIGIT drug as midphase data disappoint, promoting partner iTeos to cut costs
13.05.Leap halves head count, narrows lead cancer drug's focus amid 'difficult market environment'
13.05.Appeals court reignites CRISPR discovery row, raising questions about gene-editing biotech patents
13.05.Dutch biotech Azafaros gains €132M series B to fund phase 3 trials of brain-penetrant drug
13.05.Galapagos gets cold feet over plans to split up company
12.05.Former Inhibikase leader launches new biotech for midstage Parkinson's asset
12.05.Tango dances away from preclinical work to extend cash runway, while Avalo lays out spending options
12.05.Lexeo laid off 15% of staff in April to focus on lead cardiac gene therapies
12.05.Dynavax's feud with activist investor heats up ahead of annual meeting